The official twitter account, promoting the Sputnik V COVID-19 vaccine, tweeted on 20 January 2021 that Russian Direct Investment Fund (RDIF), Russia's sovereign wealth fund, has filed for registration of the COVID-19 Sputnik V in the European Union and expects it to be reviewed in February 2021, Reuters news agency reported on Wednesday.
This moves the vaccine closer to a wider adoption across the globe.
The Sputnik V twitter account said that teams from the vaccine and the European Medical Agency (EMA) held a scientific review of the vaccine on 19 January 2021, adding that the EMA will take a decision on the authorisation of the vaccine based on the reviews.
RDIF's chief, Kirill Dmitriev, had said in an interview at the Reuters Next conference last week that Russia would submit a formal application to the European Union in February 2021 for approval of its Sputnik V COVID-19 vaccine.
Reportedly, the Sputnik V vaccine has already been approved in Argentina, Belarus, Serbia and other countries.
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Micron Biomedical names new scientific advisor to CEO
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences